David Wambeke Purchases 33,333 Shares of NeuroOne Medical Technologies (NASDAQ:NMTC) Stock

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) insider David Wambeke bought 33,333 shares of the business’s stock in a transaction dated Thursday, August 27th. The stock was bought at an average cost of $2.01 per share, for a total transaction of $66,999.33. Following the completion of the purchase, the insider owned 199,999 shares of the company’s stock, valued at approximately $401,997.99. The trade was a 20.00% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

NeuroOne Medical Technologies Price Performance

NMTC opened at $1.66 on Thursday. The stock has a 50-day moving average price of $2.03 and a 200-day moving average price of $3.40. The firm has a market cap of $15.12 million, a PE ratio of -1.75 and a beta of 0.65. NeuroOne Medical Technologies Corporation has a 1 year low of $1.42 and a 1 year high of $6.96.

NeuroOne Medical Technologies (NASDAQ:NMTC) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.07). The firm had revenue of $1.97 million for the quarter, compared to analysts’ expectations of $2.17 million. NeuroOne Medical Technologies had a negative net margin of 71.50% and a negative return on equity of 128.12%. As a group, sell-side analysts anticipate that NeuroOne Medical Technologies Corporation will post -0.39 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Weiss Ratings downgraded shares of NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st. Maxim Group set a $5.00 price objective on NeuroOne Medical Technologies and gave the company a “buy” rating in a research report on Friday, August 14th. Finally, LADENBURG THALM/SH SH increased their target price on NeuroOne Medical Technologies from $1.60 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $7.33.

Institutional Trading of NeuroOne Medical Technologies

Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of NeuroOne Medical Technologies by 31.2% during the third quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock valued at $1,403,000 after purchasing an additional 375,639 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in NeuroOne Medical Technologies by 10.2% in the fourth quarter. Renaissance Technologies LLC now owns 763,028 shares of the company’s stock worth $578,000 after purchasing an additional 70,428 shares during the last quarter. Bard Associates Inc. bought a new stake in NeuroOne Medical Technologies in the 2nd quarter worth approximately $929,000. Essex Investment Management Co. LLC bought a new stake in NeuroOne Medical Technologies in the 4th quarter worth approximately $143,000. Finally, Virtu Financial LLC purchased a new stake in NeuroOne Medical Technologies during the 3rd quarter valued at $88,000. 16.07% of the stock is currently owned by institutional investors.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.